Insulin analogs: evidence, FDA status and research

They are changed versions of insulin that work faster or last longer for people with diabetes. Trials, including one of 756 adults, show the same blood sugar control with fewer night-time lows.

Sold for

Insulin analogs are the modified insulins that act faster at meals or last longer overnight than the human insulin they replaced, and they dominate diabetes treatment.

Studies say

Randomised trials show analogs match human insulin on blood glucose and reduce hypoglycaemia, particularly at night, which is the basis of their approvals and the A grade.

Why grade A. Every insulin analog was approved on randomised trials against human insulin. The cited Treat-to-Target trial randomised 756 adults with type 2 diabetes to glargine or NPH insulin added to oral drugs for 24 weeks and found the same glucose control with fewer night-time lows on glargine. ²³

FDA. Insulin analogs are FDA-approved to improve glycaemic control in diabetes: rapid-acting lispro (Humalog, 1996), aspart and glulisine, and long-acting glargine (2000), detemir and degludec, among others, with biosimilar and interchangeable versions now on the market. Novo Nordisk discontinued Levemir (insulin detemir) in the US at the end of 2024. ³¹

Written from 3 cited sources. Fact-checked 2026-10-27: 12 claims checked, 1 corrected, 1 sources unreachable. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Controlling blood sugar in diabetes
Can a US doctor prescribe it?: Yes, FDA approved for controlling blood sugar in diabetes.
Properly tested in people?: Yes, in large controlled trials, including one of 756 adults.

Evidence checklist

Randomised controlled trial Treat-to-Target and other randomized trialsyes
Human study over 100 people Treat-to-Target, 756 adultsyes
More than one research group Many trials, products, and sponsorsyes
Clinical outcomes, not surrogate markers HbA1c and night lows, not complicationsno
Human safety data beyond case reports Decades of use; ORIGIN found no cancer signalyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Insulin analogs are human insulin with one or a few amino acids changed or a chemical group attached so that the molecule absorbs faster or slower from under the skin. Human insulin injected before a meal takes 30 to 60 minutes to start working and peaks late; the body's own insulin responds within minutes. Rapid-acting analogs such as lispro, aspart and glulisine close that gap. ³

Long-acting analogs go the other way. Glargine precipitates at the injection site and dissolves slowly; detemir carries a fatty acid that binds albumin; degludec forms long chains that release gradually. Each provides a flat background level over a day or more, replacing NPH insulin, whose peak caused night-time hypoglycaemia. ²¹

How it works

All insulins act on the same receptor, telling muscle and fat cells to take up glucose and the liver to stop releasing it. The analogs do not act differently once in the blood; what changes is how quickly they get there. Lispro swaps two amino acids at the end of the B chain so that molecules do not stick together in hexamers and absorb as single units within 15 minutes. Glargine's added amino acids shift its solubility so it is clear in the acidic vial but forms microcrystals at the neutral pH of tissue, from which it dissolves over about 24 hours. ³²

What human research shows

In the Treat-to-Target trial, Riddle and colleagues randomised 756 overweight adults with type 2 diabetes poorly controlled on oral drugs to bedtime glargine or NPH, both titrated to a fasting glucose goal, for 24 weeks. Nearly 60% of each group reached an HbA1c of 7% or below. Glargine caused significantly less nocturnal hypoglycaemia, rates of other categories of symptomatic hypoglycaemia were 21 to 48% lower, and about 25% more patients on glargine (33.2% against 26.7%) reached the HbA1c goal without a documented night-time low. ²

Rapid-acting analogs have shown modest reductions in post-meal glucose and hypoglycaemia against regular human insulin in type 1 diabetes, with little difference in HbA1c, which is why their main advantage is practical: they can be injected right before eating. ³

Study	Model	Finding
Treat-to-Target, Riddle 2003	Humans, n=756 adults with type 2 diabetes, randomised open-label, 24 weeks	Glargine and NPH reached the same HbA1c (6.96% vs 6.97%), with significantly less nocturnal hypoglycaemia and 21 to 48% lower rates of other symptomatic hypoglycaemia on glargine. ²
Humalog prescribing information	FDA label summarising registration trials	Insulin lispro approved in 1996 as a rapid-acting mealtime insulin for adults and children with diabetes. ³

Safety

Hypoglycaemia is the central risk of any insulin, and the analogs reduce but do not remove it. Weight gain, injection-site lipodystrophy and, rarely, allergic reactions are shared across the class. Insulin glargine was investigated for a possible cancer signal in 2009 observational studies; a large randomised trial (ORIGIN) and subsequent analyses did not confirm it. Cost in the US has been the practical safety problem, with patients rationing doses; list prices fell in 2023 and 2024 and several biosimilars are now sold. The Levemir withdrawal left patients to switch to other basal insulins. ³¹²

Questions for your clinician

Which insulin type suits my meal and sleep pattern?
How can I lower my risk of night-time lows?
What are my options for costs and biosimilar versions?

Questions people ask

Are insulin analogs FDA-approved?

Yes. Lispro was the first in 1996, glargine followed in 2000, and aspart, glulisine, detemir and degludec came after. Biosimilar versions of glargine, lispro and aspart have also been approved. ³¹

What happened to Levemir?

Novo Nordisk discontinued all Levemir (insulin detemir) presentations in the US during 2024, with the vial the last to go at the end of December, citing manufacturing constraints and lost formulary coverage. Patients were moved to other basal insulins. ¹

Are analogs better than human insulin?

They give similar HbA1c with less hypoglycaemia, especially overnight for the long-acting ones, and more flexible meal timing for the rapid ones. In the 756-patient Treat-to-Target trial, glargine matched NPH on glucose control with significantly less night-time hypoglycaemia and up to 48% lower rates of other symptomatic lows. ²

Why are there so many kinds?

Because each modification trades off speed and duration. Rapid analogs cover meals; long-acting analogs cover the background need; premixed products combine both. Choice depends on the type of diabetes, the eating pattern and the cost. ³²

Citations

Novo Nordisk: Levemir (insulin detemir) discontinuation information novocare.com
Riddle 2003, Diabetes Care: the Treat-to-Target trial, glargine versus NPH added to oral therapy in type 2 diabetes doi.org
Eli Lilly: Humalog (insulin lispro) prescribing information uspl.lilly.com